Retatrutide Reconstitution Math Retatrutide - mg per dose at common vial sizes Vial Size 5 mg BAC Water 1.0 mL Concentration 5 mg/mL 2 mg Dose 0.40 mL (40 units) 4 mg Dose 0.80 mL (80 units) 6 mg Dose N/A 9 mg Dose N/A Vial Size 10 mg BAC Water 1.0 mL Concentration 10 mg/mL 2 mg Dose 0.20 mL (20 units) 4 mg Dose 0.40 mL (40 units) 6 mg Dose 0.60 mL (60 units) 9 mg Dose 0.90 mL (90 units) Vial Size 10 mg BAC Water 2.0 mL Concentration 5 mg/mL 2 mg Dose 0.40 mL (40 units) 4 mg Dose 0.80 mL (80 units) 6 mg Dose 1.20 mL (120 units*) 9 mg Dose 1.80 mL (180 units*) Vial Size 20 mg BAC Water 2.0 mL Concentration 10 mg/mL 2 mg Dose 0.20 mL (20 units) 4 mg Dose 0.40 mL (40 units) 6 mg Dose 0.60 mL (60 units) 9 mg Dose 0.90 mL (90 units) Vial Size 30 mg BAC Water 3.0 mL Concentration 10 mg/mL 2 mg Dose 0.20 mL (20 units) 4 mg Dose 0.40 mL (40 units) 6 mg Dose 0.60 mL (60 units) 9 mg Dose 0.90 mL (90 units) * Volume above 100 units exceeds a standard 1 mL insulin syringe - split into two injections or use a larger syringe

Tubular dysfunction, medication interactions, or volume status changes can all show up here
The medication (morphine (16 mg/kg s.c.), the tested agents (gastric pentadecapeptide BPC 157 (10 pg, 10 ng and 10 g/kg i.p.), naloxone (10 mg/kg s.c.), haloperidol (1 mg/kg i.p.) or saline (5 ml/kg i.p.) was given accordingly at either 30 min, 20 min or 10 min before the first assessment (time "0"), and subsequently, the mice were assessed at 15, 30, 45, 60, 90, 120, 150 and 180 min intervals (time "+")
Who Benefits and Who Should Avoid Lip C Therapy Lip C injection may be considered for patients with confirmed metabolic slowing, fatty liver disease, or metabolic syndrome seeking adjunctive metabolic support under medical supervision